Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban)
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL.
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE).
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Padlock Therapeutics, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.
AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke
- Details
- Category: AstraZeneca
AstraZeneca today announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA).
Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced positive top-line results for romosozumab from the pivotal Phase 3 placeBo-contRolled study evaluatIng the efficacy anD safety of romosozumab in treatinG mEn with osteoporosis (BRIDGE).
Abbott's Absorb, the first fully dissolving heart stent, earns positive review by FDA advisory committee
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks.
Pfizer celebrates a year of achievements in 2015 annual review
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships.
More Pharma News ...
- FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer
- Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
- Pfizer commences $5 billion accelerated share repurchase
- AstraZeneca's potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation
- Sanofi Pasteur and MSD announce intent to end joint vaccines operations in Europe
- GSK names winners of 2015 Discovery Fast Track Challenge
- Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies